Lv2
130 积分 2025-05-30 加入
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
2个月前
已完结
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
2个月前
已完结
Age‐based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study
2个月前
已完结
Drug-induced hypertension is associated with improved survival in glioblastoma patients treated with bevacizumab: evidence from a time-to-event meta-analysis and meta-regression
2个月前
已完结
Microsatellite Instability as a Biomarker for PD-1 Blockade
2个月前
已完结
MA15.07 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-small Cell Lung Cancer Patients ≥75 Years Old of Age
2个月前
已关闭
CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer
3个月前
已完结
MA15.07 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-small Cell Lung Cancer Patients ≥75 Years Old of Age
3个月前
已关闭
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
3个月前
已完结
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
3个月前
已完结
皖公网安备34019202002308
